2022
1. Mizutani D, Tokuda H, Onuma T, Uematsu K, Nakashima D, Ueda K, Doi T, Enomoto Y,
Matsushima-Nishiwaki R, Ogura S, Iida H, Kozawa O and Iwama T.
Amyloid β protein negatively regulates human platelet activation induced by thrombin receptor-activating protein.
Biosci. Biotechnol. Biochem. 2022;86:185-196.
2. Hioki T, Kuroyanagi G, Fujita K, Sakai G, Kawabata T, Kim W, Tachi J, Matsushima- Nishiwaki R, Iida H, Kozawa O and Tokuda H.
Incretins enhance PGF2α-induced synthesis of IL-6 and osteoprotegerin in osteoblasts.
Horm. Met. Res.2022;54:42-49.
3.Matsushima-Nishiwaki R, Yamada N, Hattori Y, Hosokawa Y, Tachi J, Hori T and Kozawa O.
SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway.
PLoS One 2022;17:e0262485.
4. Kuroyanagi G, Kawabata T, Tokuda H, Fujita K, Matsushima-Nishiwaki R, Sakai G, Tachi J, Hioki T, Kim W, Iida H, Otsuka T and Kozawa O.
Attenuation by HSP90 inhibitors of EGF-elicited migration of osteoblasts: involvement of p44/p42 MAP kinase.
Connect. Tissue Res.2022;63:359-369.
5. Doi T, Hioki T, Tachi J, Ueda K, Matsushima-Nishiwaki R, Iida H, Ogura S, Kozawa O and Tokuda H.
Oncostatin M reduces the synthesis of macrophage-colony stimulating factor stimulated by TGF-β via suppression of p44/p42 MAP kinase and JNK in osteoblasts.
Biomed. Res. 2022,43:41-51.
6. Kuroyanagi G, Tokuda H, Fujita K, Kawabata T, Sakai G, Kim W, Hioki T, Tachi J, Matsushima-Nishiwaki R, Otsuka T, Iida H and Kozawa O.
Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts.
BMC Musculoskelet. Disord. 2022;23:495.
7. Doi T, Hori T, Onuma T, Mizutani D, Ueda K, Enomoto Y, Matsushima-Nishiwaki R, Tanabe K, Hioki T, Tokuda H, Iwama T, Iida H, Kozawa O and Ogura S.
Thrombopoietin and collagen in low doses cooperatively induce human platelet activation.
Acute Med. Surg. 2022;9:e769.
Amyloid β protein negatively regulates human platelet activation induced by thrombin receptor-activating protein.
Biosci. Biotechnol. Biochem. 2022;86:185-196.
2. Hioki T, Kuroyanagi G, Fujita K, Sakai G, Kawabata T, Kim W, Tachi J, Matsushima- Nishiwaki R, Iida H, Kozawa O and Tokuda H.
Incretins enhance PGF2α-induced synthesis of IL-6 and osteoprotegerin in osteoblasts.
Horm. Met. Res.2022;54:42-49.
3.Matsushima-Nishiwaki R, Yamada N, Hattori Y, Hosokawa Y, Tachi J, Hori T and Kozawa O.
SERMs (selective estrogen receptor modulator), acting as estrogen receptor β agonists in hepatocellular carcinoma cells, inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway.
PLoS One 2022;17:e0262485.
4. Kuroyanagi G, Kawabata T, Tokuda H, Fujita K, Matsushima-Nishiwaki R, Sakai G, Tachi J, Hioki T, Kim W, Iida H, Otsuka T and Kozawa O.
Attenuation by HSP90 inhibitors of EGF-elicited migration of osteoblasts: involvement of p44/p42 MAP kinase.
Connect. Tissue Res.2022;63:359-369.
5. Doi T, Hioki T, Tachi J, Ueda K, Matsushima-Nishiwaki R, Iida H, Ogura S, Kozawa O and Tokuda H.
Oncostatin M reduces the synthesis of macrophage-colony stimulating factor stimulated by TGF-β via suppression of p44/p42 MAP kinase and JNK in osteoblasts.
Biomed. Res. 2022,43:41-51.
6. Kuroyanagi G, Tokuda H, Fujita K, Kawabata T, Sakai G, Kim W, Hioki T, Tachi J, Matsushima-Nishiwaki R, Otsuka T, Iida H and Kozawa O.
Upregulation of TGF-β-induced HSP27 by HSP90 inhibitors in osteoblasts.
BMC Musculoskelet. Disord. 2022;23:495.
7. Doi T, Hori T, Onuma T, Mizutani D, Ueda K, Enomoto Y, Matsushima-Nishiwaki R, Tanabe K, Hioki T, Tokuda H, Iwama T, Iida H, Kozawa O and Ogura S.
Thrombopoietin and collagen in low doses cooperatively induce human platelet activation.
Acute Med. Surg. 2022;9:e769.